Medical devices having homogeneous charge density and methods for making same
US-9170349-B2 · Oct 27, 2015 · US
US11834547B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11834547-B2 |
| Application number | US-202117184716-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 25, 2021 |
| Priority date | Jan 30, 2018 |
| Publication date | Dec 5, 2023 |
| Grant date | Dec 5, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are ophthalmic devices comprised of a reaction product of a composition comprising: (i) a crosslinked substrate network containing covalently bound activatable free radical initiators; and (ii) a grafting composition containing one or more ethylenically unsaturated compounds. Also provided are processes for making ophthalmic devices.
Opening claim text (preview).
We claim: 1. An ophthalmic device comprised of a reaction product of a composition comprising: (i) a crosslinked substrate network containing covalently bound monoacylphosphine oxide activatable free radical initiators; and (ii) a grafting composition containing one or more ethylenically unsaturated compounds. 2. The ophthalmic device of claim 1 wherein the grafting composition further comprises a crosslinker. 3. The ophthalmic device of claim 1 wherein the crosslinked substrate network is the reaction product of a first reactive composition comprising: (i) a polymerization initiator that is capable, upon a first activation, of forming two or more free radical groups, at least one of which is further activatable by subsequent activation; (ii) one or more ethylenically unsaturated compounds; and (iii) a crosslinker. 4. The ophthalmic device of claim 1 wherein the one or more ethylenically unsaturated compounds in the grafting composition and the first reactive composition comprise polymerizable groups independently selected from: (meth)acrylate, (meth)acrylamide, styryl, vinyl, N-vinyl lactam, N-vinylamide, O-vinylether, O-vinylcarbonate, O-vinylcarbamate, C 2-12 alkenyl, C 2-12 alkenylphenyl, C 2-12 alkenylnaphthyl, and C 2-6 alkenylphenyl-C 1-6 alkyl. 5. The ophthalmic device of claim 1 wherein the crosslinked substrate network is formed from one or more silicone-containing components and the grafting composition contains hydrophilic reactive components. 6. The ophthalmic device of claim 1 wherein the crosslinked substrate network is formed from one or more hydrophilic reactive components and the grafting composition contains one or more silicone-containing components. 7. The ophthalmic device of claim 1 wherein the crosslinked substrate network is formed from one or more hydrophilic reactive components and the grafting composition contains hydrophilic reactive components. 8. The ophthalmic device of claim 1 wherein the crosslinked substrate network is formed from one or more silicone-containing components and the grafting composition contains one or more silicone-containing components. 9. The ophthalmic device of claim 1 wherein the crosslinked substrate network, the grafting composition, or both the crosslinked substrate network and the grafting composition contain one or more additives selected from UV absorbers, photochromic compounds, pharmaceutical compounds, nutraceutical compounds, antimicrobial compounds, tints, pigments, dyes, release agents, and wetting agents. 10. The ophthalmic device of claim 1 wherein the concentration of the grafting composition is greater at the crosslinked substrate network's surface than at its core. 11. The ophthalmic device of claim 1 that is selected from the group consisting of a contact lens, an intraocular lens, a punctal plug and an ocular insert.
Polysiloxanes · CPC title
Hydrating contact lenses · CPC title
enabling passage of fluids, e.g. oxygen, tears, between the area under the lens and the lens exterior · CPC title
Polysiloxanes · CPC title
with vinyl compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.